<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983655</url>
  </required_header>
  <id_info>
    <org_study_id>GER-2962-19-20-1</org_study_id>
    <nct_id>NCT03983655</nct_id>
  </id_info>
  <brief_title>Effect of High Frequency/Low Intensity Transcranial Magnetic Stimulation in Cognitive Traits of an Elderly Population of Subjects With Mild Cognitive Impairment and Mild Dementia.</brief_title>
  <official_title>Effect of High Frequency/Low Intensity Transcranial Magnetic Stimulation in Cognitive Traits of an Elderly Population of Subjects With Mild Cognitive Impairment and Mild Dementia: A Randomized, Double Blind, Parallel Group, Sham Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actipulse Neuroscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no pharmacological interventions that delay or prevent the transition of mild&#xD;
      cognitive impairment to dementia. Several studies have shown that transcranial magnetic&#xD;
      stimulation (TMS) could be useful in increasing cognitive traits in dementia.&#xD;
&#xD;
      As TMS is performed in a clinical setting, transportation, mobility and high costs of&#xD;
      treatment, limit the number of TMS sessions dementia patients can receive. Most of the trials&#xD;
      do not apply more than 20 TMS sessions&#xD;
&#xD;
      Here, a randomized, sham controlled, paralallel group, clinical trial will be performed in&#xD;
      order to asess the efficacy at improving cognitive traits of a novel TMS device that uses&#xD;
      high frequency and low intensity pulses. As the device is portable and can be used from home&#xD;
      without clinical supervision, the stimulation will be applied two times per day for a period&#xD;
      of 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    COVID-19 pandemic&#xD;
  </why_stopped>
  <start_date type="Actual">May 17, 2019</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients suffering any kind of adverse effect</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Katz Index of Independence in Activities of Daily Living at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Katz Index of Independence in Activities of Daily Living at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Lawton Instrumental Activities of Daily Living Scale at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Lawton Instrumental Activities of Daily Living Scale at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Geriatric Depression Scale at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Geriatric Depression Scale at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Montreal Cognitive Assessment at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Montreal Cognitive Assessment at 6 monts</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Frontal Asessment Battery at 3 monts</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Frontal Asessment Battery at 6 monts</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline ADAS-COG at 6 monts</measure>
    <time_frame>6 months</time_frame>
    <description>Alzheimer´s Disease Assessment Scale-Cognitive</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Mild Dementia</condition>
  <arm_group>
    <arm_group_label>Real High Frequency Low Intensity TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device emits a pulsed magnetic field at an aproximate frequency of 125 hz and an intensity of 10 gauss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham High Frequency Low Intensity TMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device does not emit a magnetic field.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Frequency Low Intensity TMS</intervention_name>
    <description>125 hz, 10 gauss, 2 times daily for 6 monts</description>
    <arm_group_label>Real High Frequency Low Intensity TMS</arm_group_label>
    <arm_group_label>Sham High Frequency Low Intensity TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        IInclusion Criteria:&#xD;
&#xD;
        ( - ) CDR less or equal to 1 ( - ) Mild cognitive impairment by Petersen criteria ( - )&#xD;
        Conserved or corrected sight ( - ) Enrolled at INCMNSZ for medical care ( - ) Be able to&#xD;
        read and write ( - ) Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        ( - ) Other neurodegenerative disorder different than mild cognitive impairment or mild&#xD;
        dementia ( - ) Metabolic disease without medical care ( - ) Epilepsy ( - ) Deep brain&#xD;
        stimulator ( - ) Metalic prosthethics in the skulls ( - ) Major depressive disorder ( - )&#xD;
        Previous utilization of other neuromodulation technique ( - ) Signs or symptoms of&#xD;
        increased intracraneal pressure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Alberto José Mimenza Alvarado</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

